Spinally, founded by reputed doctors and entrepreneurs, disrupts chronic pain treatment. The intrathecal FuturaLead, designed for neural recording and stimulation of spinal cord, eliminates the need for opioids and transforms the lives of over 80 M individuals. Our stimulation lead precisely positioned on the spinal cord’s surface, enhancing treatment efficacy. This innovative approach recognized by top tier KOLs and industry market leaders marks a paradigm shift in pain relief therapy.
Prototype/preclinical
2.500.000€
2028
Medical devices
20%
1.000€
Share this project on your website.
Copy and paste the following code into your content.
Spinally is a pioneering neuro-technology company founded by seasoned medical, engineering, and executive professionals. Our primary objective is to revolutionize chronic pain treatment through the development of the world’s first intrathecal Spinal Cord Stimulation (SCS) lead, that can be easily and safely implanted into patient’s body.
The pain industry stands out as market of the future and the most promising investment niche. With people living longer and desiring a high quality of life, demand for effective chronic pain management solution with no addiction and side effects is ever-growing. Furthermore, imperative to eliminate opioids from therapy adds urgency to our cause.
Technologies like ours, demonstrating efficacy in pain reduction, have the potential to bring relief to countless individuals while also yielding substantial returns for those involved. Historical acquisitions in our industry underscore the immense value placed on comparable projects, further solidifying the promise of significant returns on investment. Investing in our technology means not only contributing to the betterment of countless lives but also securing lucrative opportunities in a burgeoning market with proven success.
Extensive testing, simulations, and scientific publications indicate that our innovation addresses the limitations of conventional, epidurally implanted products. FuturaLead enhances electrical performance and extends its reach to a broader spectrum of neurons, allowing us to address more severe and widespread pain sensations throughout the body.
Our technology delivers unparalleled quality in neural signal recording, opening the door to personalized SCS therapy. The patented invention not only promises sustainable and effective chronic pain treatment but also presents opportunities in neurorehabilitation, neurorestoration, spasticity, Parkinson’s, Refractory Angina Pectoris, and various other neurological disorders.
Our PCT patent has passed the international search report with favorable results, published in multiple countries, and is expected to be granted in the EU countries, the UK, and other regions in the coming months.
Our goal is to provide key market players (Medtronic, Boston Scientific, Abbott, Saluda, Nevro) with technology that enhances the effectiveness of their therapy while remaining compatible with their stimulation generators, making SCS as widely available and used as it is for pacemakers.
Market projections indicate substantial growth in the Chronic Pain Treatment Market, expected to reach around $145 billion by 2030, with a CAGR of about 7.1% (2020-2030). The Global Neurostimulation Devices Market is projected to reach $20 billion by 2030, with a CAGR of 11.7%, making acquisitions in this field highly valued (to mention just a few: Axonics by Boston Scientific for $3.7 Bn, Relievant by Boston Scientific for $850 M + royalties, Spinal Modulation by St. Jude for $215 M).
In addition to the team’s expertise and knowledge, Spinally has established collaborations with research institutes and service providers for regulatory, certification, fast prototyping, and manufacturing across Europe, the USA, and Australia (see section ‘Partners’).
One of our most significant sources of pride is the recognition and appreciation of our idea by professionals in the field. Our invention has won prizes and grants, including progressing to the final stage of the US NIH $2 million grant, as well as INS and ESRA smaller grants (results soon). Renowned KOLs such as Dr. Eric Grigsby and Dr. David Abejon have joined us as scientific advisors.
With successful tests, patent applications, and ethics committee approval obtained in December 2023, we are poised to fabricate the final prototype and conduct feasibility trials on the sheep model. These trials will confirm implantability, high-quality recording, precise and deep stimulation, and include a head-to-head comparison between conventional (epidural) leads and our intrathecal solution to demonstrate unmatched effectiveness. The next stage of development will encompass company certification, biocompatibility tests, regulatory GLP studies, and our first in-human trial.
How confident we are? First off, our understanding of the human nervous system and how it ties into treating pain with SCS is solid. Plus, independent publications back up our calculations and tests. Moreover, we genuinely tackle the shortcomings of market leaders. Our solution is a game-changer, revolutionizing the use of neuromodulation and recording at the spine level, a frontier that hasn’t been explored much yet.
Our ultimate goal is to secure the acquisition of our FuturaLead exclusively for pain treatment by a key market player. Simultaneously, Spinally aim to continue implementing our groundbreaking neuro-technology for other indications. To achieve this, we have already initiated discussions with clinicians and researchers working on various diseases.
Chronic pain, a major cause of disability worldwide, affects 18-34.5% of adults and incurs significant economic costs. There is an urgent need for innovation in this market, particularly in alternative technologies to opioids, one of the biggest current epidemics.
The spinal cord stimulation (SCS) device market is rapidly growing within the neuromodulation sector, projected to reach $20 billion by 2030. However, current technology faces limitations, especially in the implantation of electrodes in the epidural space, resulting in reduced electrical efficiency and compromised therapeutic precision. A major associated problem is the daily need to recharge these devices, similar to charging a mobile phone.
Spinally has developed a smaller and more efficient SCS device, named Futura Lead, which is 120 times more energy-efficient and is implanted without surgery. This advancement, which reduces the need for daily recharging to every three months, is crucial for both users and physicians.
The Spinally team combines technical and scientific knowledge, integrating experts from biotechnology companies with experience in leading companies from their inception to valuations of around $100 million and in raising more than $100 million in investments.
The team’s scientific expertise in this field is exceptional, and the technology has great scientific potential, but it is still in the preclinical phase, with a development path ahead before reaching the market.
The long road to market entails some inherent commercial risks, such as the development of other solutions. However, their exit strategy through acquisition by a leading company is feasible and significantly reduces the risk.
Already have an account? Please login here .